Revolution Medicines, Inc. Common Stock
RVMD
$203.35
-2.08%
Revolution Medicines, Inc. is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers, leveraging its proprietary structure-based drug discovery platform to create small molecules that bind to unconventional sites on RAS proteins. As a pioneer in the RAS inhibitor space, the company is positioned as a potential leader in a high-unmet-need area, with its lead candidate daraxonrasib recently demonstrating a survival benefit in a Phase 3 pancreatic cancer trial. The stock has surged over 400% in the past year, driven by rapid FDA approval of Rasonque and a $2.2 billion capital raise, but the debate centers on whether the current valuation already prices in the full commercial potential of its pipeline.…
RVMD
Revolution Medicines, Inc. Common Stock
$203.35
Related headlines
Investment Opinion: Should I buy RVMD Today?
Based on the strong clinical momentum, rapid FDA approval, and analyst consensus of 'Strong Buy' with an average target of $248.77, I rate RVMD as a Buy for investors with a high risk tolerance and a long-term horizon. The thesis is that Rasonque and daraxonrasib have the potential to become blockbuster drugs in RAS-addicted cancers, and the recent capital raise provides the financial runway to execute. However, the stock is not suitable for conservative investors due to its pre-revenue status and extreme volatility.
Sign up to view all
RVMD 12-Month Price Forecast
The AI assessment is bullish on RVMD given the strong clinical and regulatory momentum, but with medium confidence due to the high valuation and execution risks. The stock's 439% surge already reflects much of the good news, so the upside is more modest from here. Key developments to watch include Rasonque's launch metrics, daraxonrasib's ongoing trials, and any competitive moves. If the company delivers on its revenue projections, the stock could re-rate higher, but any stumble could lead to a sharp correction. I would upgrade to a more bullish stance if early sales exceed expectations, and downgrade if clinical data disappoints.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $250.46 and implied upside of +23.2% versus the current price.
Average Target
$250.46
0 analysts
Implied Upside
+23.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$179 - $320
Analyst target range
The analyst target range spans from a low of $179.00 to a high of $320.00, indicating a wide dispersion of expectations. The low target suggests some analysts see limited upside, possibly due to concerns about competition or clinical setbacks, while the high target implies significant upside potential, likely assuming successful launch and peak sales of $11.5 billion. Recent institutional actions have been uniformly positive, with firms like Guggenheim, HC Wainwright, and Mizuho reiterating Buy or Outperform ratings in July 2026, and no downgrades observed. This broad bullish sentiment, combined with the wide target range, highlights the high uncertainty inherent in a clinical-stage biotech, but the overall signal is strongly positive.
Bulls vs Bears: RVMD Investment Factors
Revolution Medicines presents a compelling bull case driven by rapid FDA approval, transformative clinical data, and a strong balance sheet, but the bear case centers on a valuation that already prices in substantial success and the inherent risks of a pre-revenue biotech. Currently, the bull evidence is stronger given the validated science and clear regulatory path, yet the stock's 439% run and premium valuation make it vulnerable to any negative surprise. The central tension is whether the market's expectations for peak sales of $11.5 billion are realistic or overly optimistic, as this will determine if the stock can grow into its valuation or face a significant correction.
Bullish
- Rapid FDA Approval Validates Pipeline: Rasonque received FDA approval just one month after filing, a remarkably fast review that underscores the strength of the clinical data and the high unmet need in RAS-addicted cancers. This regulatory success de-risks the lead asset and provides a clear path to commercialization, with analysts projecting peak sales of $11.5 billion.
- Phase 3 Pancreatic Cancer Data Doubles Survival: Daraxonrasib demonstrated a survival benefit that doubled progression-free survival versus chemotherapy in a Phase 3 pancreatic cancer trial, a landmark result in a notoriously difficult-to-treat disease. This data point, reported in April 2026, drove a significant rally and positions the drug as a potential standard-of-care, expanding the total addressable market.
- Strong Analyst Consensus and High Targets: With 21 analysts covering the stock, the consensus rating is 'Strong Buy' (mean 1.27), and the average price target of $248.77 implies 18.4% upside from the current price of $210.02. The high target of $320 suggests potential upside of 52.4%, reflecting optimism about the pipeline's commercial potential.
- Massive Capital Raise De-risks Execution: The company closed an upsized public offering raising approximately $2.2 billion in April 2026, providing ample runway to fund multiple pivotal trials and commercial launch activities. This cash infusion, combined with a current ratio of 7.14, significantly reduces near-term financing risk and allows management to focus on execution.
Bearish
- Pre-Revenue with Escalating Losses: The company reported zero revenue in Q1 2026, with net losses widening to -$453.8 million from -$213.4 million a year earlier. R&D expenses surged to $344.0 million, up 67% YoY, indicating a cash burn that, despite the recent raise, will require continued access to capital markets or successful commercialization to sustain.
- Valuation Priced for Perfection: The stock trades at a price-to-book ratio of 9.28, near the high end of its three-year range of 2.16 to 12.84. After a 439% surge in the past year, the market is pricing in successful launch and peak sales of $11.5 billion, leaving little room for clinical or commercial setbacks.
- High Beta and Volatility Risk: With a beta of 1.406, the stock is highly sensitive to market swings, and its 24.95% max drawdown over the past year highlights the potential for sharp corrections. The short ratio of 5.49 indicates elevated short interest, which could exacerbate downside moves if sentiment turns.
- Competitive and Clinical Uncertainties: The RAS inhibitor space is becoming increasingly competitive, with Merck's $6.7 billion acquisition of Terns Pharmaceuticals signaling major pharma interest. Any delay or failure in ongoing trials, or a competitor's superior data, could rapidly erode the company's first-mover advantage and justify a lower valuation.
RVMD Technical Analysis
Revolution Medicines is in a powerful sustained uptrend, with the stock up 439.2% over the past year, dramatically outperforming the S&P 500's 18.65% gain. The current price of $210.02 sits at 93.6% of its 52-week range (low of $39.175, high of $224.31), indicating strong momentum and bullish sentiment, though the proximity to highs suggests the stock may be overextended in the near term. The 6-month price change of 113.4% underscores the acceleration of the trend, which has been driven by multiple clinical and regulatory catalysts.
Beta
1.41
1.41x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$42-$224
Price range past year
Annual Return
+402.7%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | -1.1% | -1.6% |
| 3m | +32.2% | +2.2% |
| 6m | +114.4% | +14.4% |
| 1y | +402.7% | +16.2% |
| ytd | +157.3% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
Revolution Medicines is a pre-revenue biotech, with zero revenue reported in the most recent quarter (Q1 2026), consistent with its clinical-stage status. The company's net loss widened to -$453.8 million in Q1 2026, compared to -$213.4 million in Q1 2025, reflecting increased R&D investment of $344.0 million, up from $205.7 million a year earlier. This escalating burn is typical for a late-stage biotech advancing multiple pivotal trials, but it underscores the need for continued financing or successful commercialization.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-1.1B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Given the company's negative net income, the price-to-sales ratio is not meaningful (PS ratio of 0), so I selected the price-to-book ratio as the primary valuation metric. The current PB ratio of 9.28 is elevated compared to the historical range, which has fluctuated between 2.16 and 12.84 over the past three years. This suggests the market is pricing in significant future growth and successful commercialization of its pipeline, as evidenced by the stock's 439% one-year gain.
PE
-13.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Revolution Medicines is a pre-revenue company with no sales, and its net loss widened to -$453.8 million in Q1 2026, up from -$213.4 million a year earlier. R&D expenses surged to $344.0 million, reflecting aggressive investment in late-stage trials, while free cash flow was -$1.07 billion over the trailing twelve months. The company's debt-to-equity ratio is low at 0.097, but the reliance on equity financing is evident from the $2.2 billion raise in April 2026, which diluted shareholders. The current ratio of 7.14 provides liquidity, but the escalating burn rate means the company will need to achieve commercial revenue or secure additional funding within the next few years to avoid financial distress.
FAQ
The key risks of holding RVMD include: (1) Clinical risk, as the pipeline is still in development, and any trial failure could significantly impact the stock. (2) Commercial risk, as Rasonque's launch may not meet expectations, given the competitive landscape. (3) Financial risk, as the company is pre-revenue and burning cash, with a net loss of -$453.8 million in Q1 2026, requiring continued access to capital. (4) Valuation risk, as the stock trades at a high price-to-book ratio of 9.28, leaving little room for error. The most severe risk is a clinical or regulatory setback that could lead to a decline toward the 52-week low of $39.175, representing a potential loss of over 80%.
The RVMD stock forecast over the next 12 months is positive, with a base case target of $248.77 (18% upside) and a bull case target of $320 (52% upside), according to analyst estimates. The bear case target is $179, implying a -15% decline. The base case assumes successful launch of Rasonque and continued pipeline progress, with a 50% probability. The bull case, with a 30% probability, assumes stronger-than-expected sales and positive clinical data. The bear case, with a 20% probability, involves commercial or clinical disappointments. Overall, the most likely scenario is moderate upside, but investors should be prepared for high volatility.
RVMD is trading at a price-to-book ratio of 9.28, which is near the high end of its historical range of 2.16 to 12.84, suggesting the market is pricing in substantial future growth. Since the company has no revenue, traditional valuation metrics like P/E are not applicable. Compared to other clinical-stage biotechs, the valuation is premium, but it is justified by the potential peak sales of $11.5 billion for Rasonque. The stock is not undervalued on a fundamental basis, but it may be fairly valued if the pipeline delivers on its promise. Investors are paying for the optionality of a potential blockbuster drug, and the valuation implies high expectations for commercial success.
RVMD is a good buy for investors with a high risk tolerance and a long-term horizon, given its strong clinical momentum and FDA approval. The stock has surged 439% in the past year, and analysts see an average upside of 18% to $248.77, with a high target of $320. However, the stock is pre-revenue and trades at a premium valuation, so it is not suitable for conservative investors. The biggest risk is that the market has already priced in much of the success, and any clinical or commercial setback could lead to a sharp decline. For those who believe in the RAS inhibitor opportunity and can withstand volatility, RVMD offers significant upside potential.
RVMD is more suitable for long-term investment, given its clinical-stage nature and the time required for drugs to reach peak sales. The stock has a beta of 1.406, indicating high volatility, which makes it risky for short-term trading. Investors should have a minimum holding period of 3-5 years to allow the pipeline to mature and commercial revenue to materialize. The company has no dividend, so returns will depend on capital appreciation. For those with a long-term horizon and high risk tolerance, RVMD offers the potential for substantial gains, but short-term traders may find the volatility challenging to navigate.